% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Bisanzi:291412,
      author       = {S. Bisanzi and D. Puliti and G. Picozzi and C. Romei and F.
                      Pistelli and A. Deliperi and G. Carreras and G. Masala and
                      G. Gorini and M. Zappa and C. Sani and L. Carrozzi and E.
                      Paci and R. Kaaks$^*$ and F. M. Carozzi and M.
                      Mascalchi$^*$},
      collaboration = {I. W. Group},
      title        = {{B}aseline {C}ell-{F}ree {DNA} {C}an {P}redict {M}alignancy
                      of {N}odules {O}bserved in the {ITALUNG} {S}creening
                      {T}rial.},
      journal      = {Cancers},
      volume       = {16},
      number       = {12},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2024-01386},
      pages        = {2276},
      year         = {2024},
      note         = {#LA:C020#},
      abstract     = {The role of total plasma cell-free DNA (cfDNA) in lung
                      cancer (LC) screening with low-dose computed tomography
                      (LDCT) is uncertain. We hypothesized that cfDNA could
                      support differentiation between malignant and benign nodules
                      observed in LDCT. The baseline cfDNA was measured in 137
                      subjects of the ITALUNG trial, including 29 subjects with
                      screen-detected LC (17 prevalent and 12 incident) and 108
                      subjects with benign nodules. The predictive capability of
                      baseline cfDNA to differentiate malignant and benign nodules
                      was compared to that of Lung-RADS classification and Brock
                      score at initial LDCT (iLDCT). Subjects with prevalent LC
                      showed both well-discriminating radiological characteristics
                      of the malignant nodule (16 of 17 were classified as
                      Lung-RADS 4) and markedly increased cfDNA (mean 18.8 ng/mL).
                      The mean diameters and Brock scores of malignant nodules at
                      iLDCT in subjects who were diagnosed with incident LC were
                      not different from those of benign nodules. However, $75\%$
                      (9/12) of subjects with incident LC showed a baseline cfDNA
                      ≥ 3.15 ng/mL, compared to $34\%$ (37/108) of subjects with
                      benign nodules (p = 0.006). Moreover, baseline cfDNA was
                      correlated (p = 0.001) with tumor growth, measured with
                      volume doubling time. In conclusion, increased baseline
                      cfDNA may help to differentiate subjects with malignant and
                      benign nodules at LDCT.},
      keywords     = {biomarkers (Other) / cell-free DNA (Other) / low-dose CT
                      (Other) / lung cancer (Other) / prediction (Other) /
                      screening (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38927981},
      pmc          = {pmc:PMC11201711},
      doi          = {10.3390/cancers16122276},
      url          = {https://inrepo02.dkfz.de/record/291412},
}